Paul Riley/LinkedIn
Jul 18, 2026, 11:54
Paul Riley: Presenting STAR Max3 at ISTH 2026
Paul Riley, Scientific Marketing Manager at Diagnostica Stago, shared a post on LinkedIn:
“Showing our FDA submission data for the STAR Max3 at ISTH – always a privilege to attend and present at ISTH, with this meeting especially meaningful because it is taking place in Paris, the location for my first ISTH 25 years ago!
A quarter century of being witness to all of the change in the field and also International Society on Thrombosis and Haemostasis (ISTH)‘s growth as an organization clinical laboratory wtd2026.
I really do feel privileged to be involved with ISTH during these times.
I will miss Paris but will make it back soon enough.”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Aug 13, 2026, 11:15Bridging Neurology and Thrombosis: Key Priorities from a New Expert Consensus Report – International Journal of Stroke
-
Aug 13, 2026, 11:05Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
-
Aug 13, 2026, 10:31Brad Wilson: Clinical Insights from the Landmark ESC 2026 Trials
-
Aug 13, 2026, 10:23Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:44Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure